ArticleProbiotics and antimicrobial proteins2026
Expression and Characterization of Recombinant Triple Laterosporulin in Chlamydomonas reinhardtii.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multicopy Expression of the Marine Antimicrobial Peptide SpgillcinProbiotics and antimicrobial proteins · 2026Article
- Microalgae, Cell Factories for Antimicrobial Peptides: A Promising Response to Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides with broad-spectrum antibacterial properties have emerged as promising candidates for combating bacterial infections. Laterosporulin (LS), a class II bacteriocin initially isolated from Brevibacillus sp. strain GI-9, has demonstrated broad-spectrum antibacterial activity and notable biochemical characteristics. However, the limited expression levels of LS in Brevibacillus sp. GI-9 restrict its potential for large-scale production and therapeutic and food preservation applications. In this study, a triple peptide comprising three tandem repeats of LS (3 × LS), tagged with C-terminal hemagglutinin (HA) and 6 × His, was successfully expressed heterologously in Chlamydomonas reinhardtii. The purified 3 × LS-HA-6 × His effectively inhibited the growth of both Gram-positive and Gram-negative bacteria. Additionally, 3 × LS-HA-6 × His demonstrated stable antibacterial activity over a wide range of temperatures and pH values and showed significant resistance to multiple proteolytic enzymes. Furthermore, 3 × LS-HA-6 × His disrupted bacterial cell membrane integrity while exhibiting nonhemolytic activity toward rabbit erythrocytes and noncytotoxicity toward HEK293T cells. These findings underscore the potential of C. reinhardtii as a promising host for the production of bioactive and biosafe LS, providing valuable insights for the development of alternative antimicrobial strategies.
Indexed as
Identifiers
40131641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.